Cimt denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for cimt are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies CIMT as Experimental — and Why You Can Appeal

Constraint-Induced Movement Therapy (CIMT) is a rehabilitative intervention for motor deficits — most often post-stroke upper-limb impairment — that uses restraint of the less-affected limb combined with intensive, massed practice of the affected limb to promote neuroplastic recovery. Despite its established evidence base, Cigna sometimes applies an "experimental or investigational" denial, asserting that the evidence does not yet meet its threshold for coverage as a proven, non-experimental treatment.

This denial is strongly contestable. CIMT is recognized as an evidence-supported intervention by major rehabilitation and neurology organizations, including the American Heart Association and the American Stroke Association, in their published stroke rehabilitation guidelines. It is not a novel or unproven technique; it has been studied extensively in peer-reviewed literature and is practiced in accredited rehabilitation settings nationwide. An experimental denial is most likely to be overturned when the appeal documents the breadth of professional society endorsement and the patient's specific clinical profile.

## Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA): File within 180 days of denial. Cigna must respond within 60 days (30 days for pre-service).
• External review (ACA §2719): Experimental/investigational denials are specifically eligible for independent external review under federal law. Request external review within approximately 4 months of the final internal denial. Independent reviewers apply generally accepted clinical standards — not the insurer's own coverage criteria.
• Expedited review: Available if clinically urgent; decision within 72 hours.

## What to Gather

1. Diagnosis and clinical indication: Physician documentation confirming the diagnosis, time post-onset, and upper-limb functional deficits that make CIMT clinically indicated. 2. Guideline and professional society endorsement: A letter from the treating physiatrist, neurologist, or therapist citing the applicable AHA/ASA stroke rehabilitation guideline recommendation for CIMT, establishing it as a recognized, non-experimental standard of care for this indication. 3. Clinical appropriateness for this patient: Documentation of why this patient meets the clinical profile for which CIMT is recommended — motor function level, time since stroke, prior therapy history, and rehabilitation potential. 4. Cigna's experimental/investigational criteria: Download Cigna's current coverage policy. Identify the specific criteria used to classify CIMT as experimental and address each one directly. 5. Functional prognosis: Therapist statement on expected functional gains and the clinical consequence of denial.

## Criteria-Mapping Structure

| Cigna Experimental/Investigational Criterion | Your Documentation | |---|---| | Not recognized by professional societies | Prescriber letter citing AHA/ASA guideline endorsement | | Insufficient peer-reviewed evidence | Physiatrist/therapist attestation of established evidence base | | Not generally accepted clinical practice | Documentation of use in accredited rehabilitation programs | | Patient meets indication profile | Diagnosis, functional status, and prior therapy records |

External review is your strongest tool here: independent reviewers regularly find that CIMT meets "generally accepted" standards even when a plan's internal policy lags professional consensus.